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Abstract: There are various factors that contribute to the development of neoplasia. Among the most important 
factors are the genetic and environmental factors. One of the strongest pieces of evidence for the genetic basis 
of cancer at the cellular level is the observation that nearly all cancers are monoclonal in origin that is all of the 
cancer cells in an individual patient can be shown to have arisen from a single original precursor cell. 
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INTRODUCTION 
There are several lines of evidence to support the 
genetic contribution to cancer. The evidence for a genetic 
origin of cancer at the somatic level includes: 
• The evidence using the X-linked polymorphic 
glucose-6-phosphate dehydrogenase marker for a 




The OCClllTence of specific chromosomal changes in 
particular forms of cancer 
The fact that many carcinogens are also mutagens 
which in many cases can be shown to act through 
their interactions with DNA 
The observation that inherited syndromes involving 
deficiencies in the ability to repair defects in DNA, 
leading to increased mutation rates are associated 
with increased twnour incidence (Barrett, 1987) 
During the past 20 years, cancer researchers have 
made dramatic progress in identifying large nwnber of 
genes that when mutated can contribute to the 
development of the cancer cell. From this large body of 
work, the general picture of cancer pathogenesis IS 
beginning to emerge (Mueller and Young, 2002). 
INHERITED CANCER SYNDROMES 
Though in any individual the development of cancer 
cannot usually be ascribed to a single inherited gene 
abnormality at the cellular level cancer is flllldamentally a 
genetic disease (Gelehrter e/ aI., 2000). 
Each hwnan cell carries a very complex and highly 
regulated genetic programme that controls normal cellular 
growth and differentiation. Cancer results from a 
disruption of this normal regulatory pattern, leading to 
llllcontrolled cellular grovvth and proliferation that is 
recognised as a malignant tumour. The development of 
cancer requires the accwnulation of multiple, sequential 
genetic mutations within a somatic cell. These somatic 
mutations are restricted to the twnour and are not fOlllld 
in the normal cells of the individual. In contrast a germ line 
mutation is present all throughout the cells of the 
individual and may be passed on to subsequent 
generations (Gelehrter e/ aI., 2000). 
Several hereditary conditions are associated with an 
increased risk of cancer. For some, this susceptibility has 
been demonstrated by comparing rates among relatives of 
cancer patients with the rates in the general population. 
F or others, the increase is so dramatic that it is evident 
after the evaluation of only a few affected families. 
Recently developed techniques of molecular biology 
are being applied to locate the gene responsible for the 
development of cancers. The knowledge of gene location 
can be applied to the early diagnosis and prevention of 
inherited cancer. Hereditary cancer syndromes for which 
the chromosomal location is kno"\iVll include hereditary 
retinoblastoma, Familial Adenomatous Polyposis (F AP), 
the Cancer Family Syndrome (CFS) or lynch syndrome, Li-
frawneni syndrome, Multiple endocrine neoplasia type 1 
and 2, dysplastic naevus syndrome, neurofibromatosis 
type 1 and 2 and Von hippellindau disease (T omatis and 
Aitio, 1990). 
THE GENETICS AND CLINICAL ASPECTS 
OF RETINOBLASTOMA 
Retinoblastoma is a relatively rare, highly malignant 
childhood cancer of the developing retinal cells of the eye 
which usually occurs before the age of 5 years. The first 
clue to the location of the retinoblastoma gene was 
provided by rare individuals who developed bilateral 
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retinoblastomas and had multiple congenital anomalies 
and developmental impairment. Retinoblastoma, the 
prototype of diseases caused by mutation of RBI gene 
has an incidence of 1 in 20,000 live births. Unlike other 
twnours, retinoblastoma is detected at a relatively early 
stage of tumour development because its easily detected 
by ophthalmoscopy. At the time of clinical detection, 
most retinoblastoma tumours are confined to the retina 
and vitreous body. Invasive grovvth into the optic nerve, 
sclera and orbits or metastases occurs only at advanced 
stages. The prognosis of patients with metastatic disease 
is poor lllllike the early stage retinoblastoma which carries 
a good long term outcome (Horsthemke. 1992). 
About 40% of cases of retinoblastoma are of the 
heritable fonn, in which the child inherits one mutant 
allele. the Retinoblastoma locus (RB!) through the 
germline (Nissbawn et al., 2004). A somatic mutation or 
other alteration in a single retinal cell leads to loss of 
fllllction of the remaining normal allele, thus initiating 
development of a twnour. 
The inherited susceptibility gene, RB 1 gene, 
according to Knudson's two mutation hypothesis is 
dominant because having inherited one abnormal gene, 
the probability of a second event occlllTing is sufficiently 
high so that this gives the individual with the single 
abnormal gene an almost certain chance of developing 
retinoblastoma. This occurs because the large nwnber of 
primordial retinoblasts and their rapid rate of proliferation 
make it very likely that a somatic mutation will occur in 
one of the retinoblasts. At the cellular level, however, the 
necessary genetic change is recessive since both copies 
of the gene must be inactivated for the twnour to develop 
(Horsthemke. 1992). 
The other 60% of cases of retinoblastoma are 
sporadic. In these cases both RBI alleles in a single retinal 
cell have been inactivated by independent somatic 
mutations. Because this is a rare event, the retinoblastoma 
that develops in this case is mrilateral and the average age 
of onset is later than the infants with the heritable form 
(Horsthemke. 1992). 
RBI GENE STRUCTURE AND FUNCTION 
Chromosomel3-specific DNA markers and positional 
cloning techniques were used to identify the RBI gene 
(Fllllg et al., 1987). The retinoblastoma protein is a 
phosphoprotein that IS hypophosphorylated and 
hyperphosphorylated at different stages of the cell cycle. 
In its hypophosphorylated state. it blocks cell cycle 
progression at the bOlllldary between the Gland S phase, 
thereby inhibiting entry into the S phase by binding to 
and inactivating transcription factors (Chellappan et al., 
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1991). As the RBI protein becomes progressively more 
heavily phosphorylated, it releases its protein binding 
partners, allowing entry of the cell in the S phase. Loss of 
the RBI gene deprives cells of an important mitotic 
checkpoint and allows llllcontrolled proliferation 
(Chellappan et 01 .• 1991). 
FAMILIAL COLON CANCER 
Familial polyposis coli is a rare autosomal dominant 
form of colon cancer that can be readily distinguished 
from sporadic colon cancer. Its prevalence IS 
approximately 1:10.000 (Anderson. 1978). Familial 
polyposis patients have a normal colon at birth but during 
the first 20 years of life hundreds of small polyps appear 
in the colon and occasionally elsewhere in the intestinal 
tract. Although, these polyps are asymptomatic their 
major significance is in the risk of progression to colon 
cancer which approximates 100% by age of 50 years in a 
patient with this disease. A pancolectomy in early 
adulthood prevents this outcome. As this condition is 
autosomal dominant, making the diagnosis in one 
individual obligates the physician to investigate the rest 
of the family, as there may be no other warning signs of 
the disease lllltil the appearance of malignancy. Because 
surgical therapy is so successful, individuals at risk 
should be evaluated with DNA testing and colonoscopy 
if indicated by the age of 20 years (Gelehrter et 01 .• 2000). 
Though the gene for familial adenomatous polyposis, 
referred to as APC gene (adenomatous polyposis coli 
gene) was first cloned in 1991, clues to its fllllction have 
have only recently begllll to emerge (Gelehrter et al., 
2000). The APC gene functions by interacting with a 
family of proteins involved in cell adhesion, regulating 
subsequent signalling to the nucleus. APC fulfills the 
criteria for a classic tumour suppressor gene with the 
second hit in familial polyposis patients eliminating 
expression of the remaining normal allele. Loss of the APC 
gene expression in a colonic mucosal cell gives rise to a 
clonal benign tumour proliferation resulting in a polyp. 
Though this single event does not by itself produce 
cancer, it is the first step that appears to markedly 
predispose the cell to the effects of other genetic events 
which eventually accwnulate to produce a frank colon 
cancer. 
This mechanism also appears 
sporadic colon cancer with at least 
to operate III 
80% of sporadic 
twnours exhibiting somatic mutation of the APC locus 
(Winawer et al., 1985). these and other studies on colon 
cancer have resulted in perhaps, the clearest example of 
the multiple genetic steps required for progression from a 
normal cell to full blo"\iVll cancer. Loss Of Heterozygosity 
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studies (LOR) on colon cancer identified a sequential 
pattern of genetic loss on chromosomes 5q,17p and 18q 
(Gelehrter et 01.. 2000). The gene on chromosome 5q 
turned out to be the APe gene and the gene on 17p is the 
p53 gene. The 18q gene. named the DCC gene for deleted 
in colon cancer is still of illlknown fllllction and gennline 
mutations in this gene have not yet been identified. For 
colon cancer to develop mutations in the ras oncogene 
also occur. Colon cancer cells lllldergo other types of 
changes and DNA modifications such as DNA 
methylation that may also contribute to the malignant 
phenotype (Gelehrter et 01.. 2000). 
HEREDITARY NON POLYPOSIS COLON CANCER 
Although, familial polyposis aCcOllllts for <1 % of 
colon cancer, familial clustering of colon cancer without 
polyps is frequently observed. These families often also 
have features associated with familial cancer syndromes 
such as YOllllger age of onset and association with other 
specific tumours such as YOlmger age of onset and 
association with other specific tlllllOurS such as ovarian 
and endometrial cancer. This syndrome is referred to as 
hereditary non polyposis colon cancer-Hl'.JPCC or Lynch 
syndrome (Freed, 1988). 
Using the methods of positional cloning, the first 
gene responsible for a subset of Hl'.JPCC families termed 
MSH2 was identified in 1993 (Gelehrter et 01 .• 2000). This 
gene is closely related to a family of genes in bacteria and 
yeast involved in the repair of DNA sequence 
mismatches. Three other genes subsequently identified in 
Hl'.JPCC families also appear to be involve in the same 
DNA repair pathway (Lynch. 1980). Though the DNA 
mismatch repair genes appear to accollllt for the majority 
of HNPCC families, additional genes probably remain to 
be identified. 
BREAST CANCER 
Hlllllan breast cancer is usually caused by genetic 
alterations of the DNA of the somatic breast ductal 
epithelial cells but occasionally susceptibility to the 
disease is inherited (Sattin et 01 .• 1985). A family history 
of breast cancer is reported to increase womans risk two 
fold to three fold. Among woman with a family history of 
breast cancer, those that have a first degree relative with 
bilateral or premenopausal breast cancer especially if they 
develop breast cancer before the age of 40 years are 
especially at high risk of developing breast cancer 
(Bain et 01.. 1980). 
Other breast cancer risk factors such as menopausal 
status, age at menarche, parity, age at first full term 
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pregnancy and history of benign breast disease have all 
been studied to determine their possible influence on the 
risk of breast cancer. The YOlmger the age at first full term 
pregnancy and the higher the multiparity the lower is the 
risk of breast cancer. However, except for parity and age 
at first full term pregnancy, different studies which 
analysed the other risk factors have yielded conflicting 
results especially on the relationship between the oral 
contraceptive pill and breast cancer (Brinton et al., 1982). 
Breast cancer has been the subject of an impressive 
nlllllber of studies which have all sho"\iVll without 
exception a two to three fold increased risk of breast 
cancer in 1 st degree relatives of patients with breast 
cancer (Anderson et al., 1958). These results are 
indicative of a strong polygenic mechanismt involvement 
of many genes exerting small effect acting in concert with 
environmental or non genetic factors which have a 
stronger and more important effect. In fact it is now 
thought that breast cancer is heterogenous i.e., breast 
cancer is due to mutations at different loci in different 
families. 
Breast cancer has long been recognised as being 
complex. Epidemiological studies have indicated a 
difference III the susceptibility between women 
developing the disease before menopause and those 
developing the disease post menopausal. The 
premenopausal type of disease is considered to involve 
exceSSIve ovarIan estrogenic activity, while the 
postmenopausal type is considered to involve estrogens 
of adrenocortical origin (De Waard et 01.. 1964). 
A genetic difference between the premenopausal and 
postmenopausal types of disease has been demonstrated. 
Various studies have shown that the risk for breast cancer 
increases significantly in first degree relatives of patients 
with premenopausal breast cancer but does not increase 
in post menopausal patients. The risk of breast cancer 
increases five fold in relatives of patients with bilateral 
disease but those with mrilateral disease the risk of 
developing breast cancer in 1 st degree relatives is much 
less. When the disease is both premenopausal and 
bilateral, the risk increases nine fold while the post 
menopausal and llllilateral patients exhibit only a 1.2 fold 
increase. The results of such studies suggest a genetic 
difference between the two types of breast cancer and a 
much stronger genetic effect in the premenopausal and 
bilateral type of disease than in the post menopausal and 
unilateral type (Anderson, 1974). 
LI FRAUMENI SYNDROME 
Families with Li frallllleni syndrome are at increased 
risk of developing a nlllllber of tlllllOurS especially soft 
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tissue sarcomas in children and and yOllllg adults and 
early onset breast cancer in their mothers and other close 
relatives. Brain tlllllOurS, leukemia, laryngeal and Itmg 
cancer, adrenocortical tlllllOurS and osteosarcomas also 
occur with increased frequency in patients with Li 
frawneni syndrome which is inherited in an autosomal 
dominant way (Glendon et 01 .• 1990). 
It has been suggested that the retinoblastoma 
susceptibility gene, located at the chromosome 13q 14 is 
involved in Li Frmnneni syndrome as well. Other possible 
gene locations include chromosome 11 and 17p which 
have been sho\Vll to be involved in the development of 
both sarcomas and breast cancers (Koufos et al., 1985). 
Families with Li Frawneni syndrome are rare but 
nevertheless recognition of such families is important in 
identifying individuals at risk who may benefit from 
genetic cOWlSelling and screening. Of wider importance, 
such families provide a model of cancer susceptibility not 
only to rare cancers such as soft tissue sarcomas but also 
to the very common malignancies such as carcinoma of 
the breast. Collaborative interdisciplinary studies of the Li 
frawneni syndrome may lead to important insights into the 
aetiology and histogenesis of a variety of cancers (Birch, 
1990). 
The mutation in Li frawneni syndrome involves the 
p53 twnour suppressor gene. The p53 regulates the cell 
cycle and is involved in a lot of anti cancer mechanisms. 
It activates DNA repair mechanisms when DNA has 
sustained damage or else it initiates apoptosis if DNA has 
sustained damaged beyond repair. So Li frawneni patients 
who inherit only one fllllctional copy of the p53, develop 
multiple tlllllOurS at an early age. 
CONCLUSION 
Although, genetic factors playa role in the aetiology 
of most of the neoplasms, there are certain neoplasms 
where the genetic contribution plays the dominant role. 
As we have considered, these include retinoblastoma, Li 
Frallllleni syndrome, hereditary breast cancer, hereditary 
non polyposis colon cancer. To make a diagnosis of these 
relatively rare syndromes, special criteria are available, as 
recognition of such families is important in identifying 
individuals at risk who may benefit from genetic 
cOWlSelling and screening. 
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